Travere Therapeutics Stock Upgraded to Overweight by Piper Sandler

Analysts raise price target to $49 amid positive outlook for rare disease drug pipeline

Apr. 14, 2026 at 4:06pm

Got story updates? Submit your updates here. ›

A highly detailed, black-and-white close-up image of complex banking machinery and mechanical components, conveying the institutional power and financial infrastructure behind Travere Therapeutics' rare disease drug pipeline.An extreme close-up of Travere Therapeutics' rare disease drug development machinery highlights the company's institutional strength and financial backing.San Diego Today

Biopharmaceutical company Travere Therapeutics (NASDAQ: TVTX) saw its stock upgraded to 'Overweight' by Piper Sandler analysts, who also raised the price target to $49 per share, representing a potential upside of 19% from the previous close.

Why it matters

Travere Therapeutics is focused on developing therapies for rare kidney and genetic disorders, an area with limited treatment options. The upgrade and higher price target signal analysts' confidence in the company's drug pipeline and commercial potential.

The details

In a research report, Piper Sandler cited Travere's lead product, sparsentan, which has received accelerated approval from the FDA, as a key driver of the positive outlook. The analysts also noted the company's broader portfolio of rare disease drug candidates in development.

  • Piper Sandler issued the upgrade and new price target on April 14, 2026.

The players

Travere Therapeutics

A biopharmaceutical company headquartered in San Diego, California, focused on developing therapies for rare kidney and genetic disorders.

Piper Sandler

A leading investment bank and research firm that covers Travere Therapeutics and other healthcare companies.

Got photos? Submit your photos here. ›

What they’re saying

“We believe Travere Therapeutics' rare disease drug pipeline, led by sparsentan, has significant commercial potential and warrants an Overweight rating.”

— Piper Sandler Analyst

What’s next

Investors will be closely watching Travere's progress with sparsentan and other drug candidates in its pipeline as the company aims to address unmet needs in rare disease treatments.

The takeaway

Travere Therapeutics' focus on rare diseases and its promising drug pipeline have caught the attention of Wall Street, with a leading investment bank upgrading the stock and raising its price target, signaling optimism about the company's future growth potential.